170 related articles for article (PubMed ID: 12208593)
1. Safety and efficacy of valsartan versus enalapril in heart failure patients.
Willenheimer R; Helmers C; Pantev E; Rydberg E; Löfdahl P; Gordon A;
Int J Cardiol; 2002 Oct; 85(2-3):261-70. PubMed ID: 12208593
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Kuwabara Y; Komuro I
Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):255-61. PubMed ID: 15768589
[No Abstract] [Full Text] [Related]
4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Kasama S; Toyama T; Hatori T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
Heart; 2006 May; 92(5):625-30. PubMed ID: 16159967
[TBL] [Abstract][Full Text] [Related]
6. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Holwerda NJ; Fogari R; Angeli P; Porcellati C; Hereng C; Oddou-Stock P; Heath R; Bodin F
J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
[TBL] [Abstract][Full Text] [Related]
7. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
8. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
9. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
10. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
[TBL] [Abstract][Full Text] [Related]
11. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Dickstein K; Chang P; Willenheimer R; Haunsø S; Remes J; Hall C; Kjekshus J
J Am Coll Cardiol; 1995 Aug; 26(2):438-45. PubMed ID: 7608448
[TBL] [Abstract][Full Text] [Related]
13. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril.
Ko GT; Tsang CC; Chan HC
Adv Ther; 2005; 22(2):155-62. PubMed ID: 16020405
[TBL] [Abstract][Full Text] [Related]
14. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
15. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
[TBL] [Abstract][Full Text] [Related]
18. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
[TBL] [Abstract][Full Text] [Related]
19. Valsartan in heart failure patients previously untreated with an ACE inhibitor.
Mazayev VP; Fomina IG; Kazakov EN; Sulimov VA; Zvereva TV; Lyusov VA; Orlov VA; Olbinskaya LI; Bolshakova TD; Sullivan J; Spormann DO
Int J Cardiol; 1998 Aug; 65(3):239-46. PubMed ID: 9740480
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
Cohn JN
Am J Cardiol; 2002 Nov; 90(9):992-3. PubMed ID: 12398968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
